Welcome to LookChem.com Sign In|Join Free

CAS

  • or

400748-70-1

Post Buying Request

400748-70-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

400748-70-1 Usage

General Description

3'-Methoxy-biphenyl-3-ylamine, also known as 3-methoxy-3-phenylbiphenylamine, is an organic compound consisting of a biphenyl core with a methoxy group and an aniline moiety. It is a pale yellow solid that is commonly used as a chemical intermediate in the production of various pharmaceuticals and organic compounds. This chemical has applications in the synthesis of dyes, pigments, and polymers, as well as in the production of specialty chemicals. It is also used as a precursor in the pharmaceutical industry, particularly in the synthesis of certain drugs and pharmaceutical intermediates. Overall, 3'-Methoxy-biphenyl-3-ylamine is a versatile and important chemical compound with various industrial applications.

Check Digit Verification of cas no

The CAS Registry Mumber 400748-70-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,0,7,4 and 8 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 400748-70:
(8*4)+(7*0)+(6*0)+(5*7)+(4*4)+(3*8)+(2*7)+(1*0)=121
121 % 10 = 1
So 400748-70-1 is a valid CAS Registry Number.

400748-70-1Relevant articles and documents

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

-

, (2020/08/28)

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

FNEW ACTIVATORS OF SIRT1 ENZYME FOR THE TREATMENT OF CARDIOVASCULAR AND CARDIOMETABOLIC PATHOLOGIES

-

Page/Page column 13; 17; 30-31, (2019/09/12)

This invention describes a class of compounds able to activate the human SIRT1 enzyme and regulate many metabolic functions. This invention relates to compounds that can be employed in medical applications, specifically for the treatment or prevention of cardiometabolic diseases, such as diabetes, and of cardiovascular disorders, such as coronaropathy, heart failure and atherosclerosis.

DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS

-

Paragraph 69; 126; 133, (2018/12/02)

The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the treatment of diseases and conditions mediated by CB1.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 400748-70-1